GMAB vs ROIV

Genmab A/S and Roivant Sciences Ltd., both Healthcare

Genmab A/S is the larger company at $33B against $28B. GMAB keeps 29 cents of operating profit from each dollar of sales against -1358 for ROIV, and ROIV grew sales faster over the last year, +102% against +19%. Over the past year ROIV returned +83% against +75% for GMAB.

Genmab A/S and Roivant Sciences Ltd. compared on valuation multiples, growth, margins and return
FigureGMABROIV
Last close$50.98$38.73
Market cap$33B$28B
Trailing P/E33.2n/a
Revenue growth+19%+102%
Operating margin29%minus 1358%
Net margin26%minus 838%
Free cash flow yield3.5%n/a
Net cash$3.6B net debtn/a
Insiders, 12 monthsn/asold $895M net
1-year return+75%+83%
5-year return+9.6%+388%

Figures from SEC filings and end-of-day closes. Highlighting marks the higher number in each row, nothing more.

Genmab A/S

Revenue of $2.1B in the quarter to Dec 31, 2025, net income $432M.

Roivant Sciences Ltd.

Revenue of $35M in the quarter to Sep 30, 2026, net income null.

Open these two in the interactive comparison to add more names, change the period or see the correlation.